Stevenage Bioscience Catalyst (SBC) has launched a free accelerator programme to give data-focused biotech start-ups the skills they need to get potential new drugs and therapies to market more quickly.
Stevenage Bioscience Catalyst
Stevenage Bioscience Catalyst is a leading location for development and commercialisation of advanced therapeutics. The Campus is home to GSK, the Cell & Gene Therapy Manufacturing Catapult, LifeArc and Cytiva plus 40+ start-up companies which together have raised £1.8 bn equity investment, IPO/FPO, grants and acquisitions since 2012. The facilities provide business support, scientific equipment and scale up advice.
Telephone: 01438 906 906
Address :
Stevenage Bioscience Catalyst Gunnels Wood Road Stevenage
Post Code: SG1 2FX
Country: United Kingdom
Website: https://www.stevenagecatalyst.com/
Membership Type: Corporate 6-20
There are no Products & Services to display
23-02-2021
Dr Sally Ann Forsyth, CEO of Stevenage Bioscience Catalyst (SBC), thanks her colleagues and collaborators after being honoured in the 2021 New Year Honours list. Sally Ann has been awarded an Officer of the Order of the British Empire (OBE) for services to business and science.
03-01-2021
Stevenage Bioscience Catalyst (SBC), a leading location for development and commercialisation of cutting-edge therapeutics, is pleased to announce the opening of the Lab Hotel, a lab and office facility for early-stage start-ups in the field of advanced therapeutics and drug discovery. Successful companies have access to the Lab Hotel facilities and support free for six months, with the first...
24-11-2020
New report shows 10% of UK’s top female BioBusiness talent is based at Stevenage Bioscience Catalyst
The report released today by BioBeat showcasing the 30 top female leaders in the UK bioscience sector has named three people from organisations based at Stevenage Bioscience Catalyst (SBC), totalling 10% of the list.
10-11-2020
Stevenage Bioscience Catalyst’s new Spark Building opened its doors in January to accommodate the rapid growth of scale-up businesses within Hertfordshire’s world-class cell and gene cluster.
14-10-2020
The Department for International Trade (DIT) has classified Stevenage, Hertfordshire, as a High Potential Opportunity (HPO) zone in recognition of its thriving cell and gene therapy cluster of national and international significance. The successful HPO nomination was made by Hertfordshire Local Enterprise Partnership (LEP) and is expected to help attract further overseas investment into the...
12-10-2020
Series B round led by Morningside Ventures provides foundation to accelerate the drug development of first-in-class immune-resetting therapies.
23-09-2020
London & Research Triangle Park, N.C. - ReViral Ltd., a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing novel antiviral therapeutics that target respiratory syncytial virus (RSV), today announced the close of a US $44 million Series C financing led by CR-CP Life Science Fund.
01-09-2020
Stevenage Bioscience Catalyst (SBC), a leading location for development and commercialisation of cutting-edge therapeutics, is pleased to announce that Professor Jackie Hunter is to take the role of Chair in September 2020.
20-08-2020
There are no events to display
There are no jobs to display
No Blog articles found
